South Dakota Cannabis
Market Intelligence Report

South Dakota's relationship with cannabis legalization has been unusually contentious. Voters approved adult-use cannabis via Constitutional Amendment A in November 2020 by a 54.18%-45.82% margin, only for the South Dakota Supreme Court to strike it down in 2021 on single-subject and constitutional-revision grounds. Voters themselves then rejected two subsequent legalization measures: Initiated Measure 27 in 2022 (53%-47% against) and Initiated Measure 29 in 2024 (roughly 56%-44% against) — with the margin against legalization widening rather than narrowing between those two votes.

Meanwhile, the state's medical cannabis program has been on its own rollercoaster. Cardholders peaked at 13,705 in February 2024, then fell 15% to 11,635 by December 2024 amid competition from hemp-derived intoxicant products, an oversupply of dispensaries relative to patient demand, and discouragement following the failed adult-use vote — triggering at least eight dispensary closures. The program has since rebounded sharply, with patient counts climbing 62% year-over-year to reach 19,247 by May 2026.

South Dakota's population of roughly 925,000 is among the smaller addressable patient bases in this report set, with household income close to the national median. (Official, Census ACS 2024)

South Dakota's medical cannabis program is regulated by the South Dakota Department of Health. The state applies a uniform $5,000 nonrefundable application fee across all establishment types — dispensaries, cultivators, manufacturers, and testing labs — for both initial applications and renewals, with processing taking up to 90 days. As of early 2025, the licensed footprint comprised 70 dispensaries, 35 cultivators, 19 manufacturers, and six testing labs, though at least eight establishments closed in late 2024 and early 2025 amid falling patient counts and intense price competition.

South Dakota does not operate a dedicated cannabis tax-incentive or grant program; its licensing structure is defined by a simple, uniform application fee rather than tiered incentives.

South Dakota's supply chain has been under real pressure since 2024. Industry sources point to hemp-derived intoxicant products — sold outside the regulated medical cannabis system under a federal farm-bill loophole — as the chief competitive threat to licensed cultivators, manufacturers, and dispensaries. The Legislature passed a bill to restrict these alternative products, but it has faced court challenges and has done little so far to curb their availability. Combined with a dispensary network that expanded faster than patient demand initially supported, this contributed to at least eight establishment closures in late 2024 and early 2025; the rebound in patient counts through 2026 has not yet been matched by public reporting on dispensary count recovery.

After a sharp 2024 contraction, patient demand has rebounded strongly enough to post the fastest year-over-year growth rate among medical-only programs in this report set. (Official)

South Dakota's 70 licensed dispensaries (early 2025 count) are distributed across the state, with the South Dakota Department of Health maintaining a public establishments list by location. The state does not publish a county-by-county sales breakdown. (Not Available — county-level sales breakdown.)

South Dakota's flat fee structure is publicly documented and consistent across license types.

Vendor demand signal tracks which product and service categories South Dakota's recovering dispensary and cultivation network are actively sourcing this quarter.

South Dakota treats medical cannabis purchases like ordinary retail sales, applying its standard 4.2% state sales and use tax (plus up to 2% local tax where applicable) rather than a dedicated cannabis excise tax. The state does not publish a consolidated cannabis tax revenue total, and with adult-use legalization rejected three times since 2020, no excise-tax revenue stream beyond standard sales tax currently exists.

South Dakota borders six states with sharply divergent cannabis policy, from established adult-use markets to full prohibition.

South Dakota does not publish a consolidated statewide cannabis-industry employment figure. With at least eight establishments closing in 2024-2025 followed by a 62% patient rebound through 2026, direct employment likely contracted before stabilizing or modestly recovering, though no official figure quantifies this. (Not Available.)

South Dakota's medical cannabis program does not include a dedicated statewide social equity license track; the $5,000 flat application fee applies uniformly to all applicants regardless of license type. (Official.)

South Dakota does not publish an official illicit or unregulated cannabis market size estimate. Industry sources have specifically identified hemp-derived intoxicant products — sold under a federal farm-bill loophole outside the licensed medical cannabis system — as a major competitive and substitution pressure on the regulated market, contributing to the 2024 patient and dispensary decline. No official dollar figure quantifies this unregulated segment. (Not Available.)

This report blends official South Dakota Department of Health licensing and patient data, state ballot-measure records, state tax guidance, and federal demographic sources. No statewide cannabis sales-revenue total is published, and that gap is flagged accordingly.

This report compiles data from the South Dakota Department of Health, state ballot and election records, reputable cannabis policy media, and federal demographic sources.